Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2014—Terumo BCT has been awarded a U.S. Department of Defense cost-share contract worth up to $29.9 million to advance the Mirasol system for the treatment of donated whole blood used in emergency transfusions to deployed military personnel.
January 2014—Chembio Diagnostics received its first purchase order for its DPP HIV-Syphilis Assay from its distributor in Mexico. The DPP HIV-Syphilis Assay is based on the company’s patented Dual Path Platform (DPP), a point-of-care testing platform that is suited to multiplexing and that adds a syphilis biomarker to the company’s FDA-approved DPP HIV 1/2 test. The addition of this marker has resulted in a fingerstick whole blood test that can help reduce the transmission of HIV and syphilis from mother to child.
January 2014—ViroStat has released three new monoclonal antibodies that have broad reactivity with several rhinovirus types. These antibodies are reactive with the VP3 capsid protein and function in ELISA and IFA to detect these viruses. Data sheets for these antibodies are available from the company.
January 2014—Immunetics introduced an updated BacTx analyzer for use with its BacTx rapid test for bacteria in whole blood–derived and apheresis platelets. The analyzer offers automated interpretation, tracking, and documentation.
January 2014—With the recent acquisition by Nuclea Biotechnologies of Wilex (Oncogene Science), Nuclea will begin its foray into the GMP manufacturing and marketing of the FDA 510(k)-cleared HER2/neu blood test out of its facility in Cambridge, Mass. The test is available as an in vitro diagnostic in the U.S., Canada, and Europe (CE mark).
January 2014—Royal Philips received 510(k) clearance from the FDA to market its HER2/neu IHC Digital Manual Read product in the U.S.
January 2014—Rainbow Scientific is offering advanced research products for human mesenchymal stem cell (hMSC) and human embryonic stem cell (hESC) culture from Biological Industries.
January 2014—Enzo Life Sciences has expanded its portfolio of drug discovery platforms with the introduction of the new Leading Light Sclerostin-LRP Screening System. Developed to meet the market need for a simple, sensitive biochemical screening assay for detection of sclerostin inhibitors (antagonists of the Wnt signaling pathway), this kit is a drug discovery tool for detecting small molecule inhibitors that disrupt the interaction between SOST and LRP5.
January 2014—Diagnostic BioSystems introduces a new chromogen to its color spectrum, PermaRed/HRP. This HRP-based substrate/chromogen system produces a sharp, contrasting brick red color.
January 2014—TriLink BioTechnologies has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna’s freeze-drying (lyophilized) contract development and production service.
